InMode (NASDAQ:INMD) Stock Price Up 3.9%

InMode Ltd. (NASDAQ:INMD) shares rose 3.9% during mid-day trading on Tuesday . The stock traded as high as $58.76 and last traded at $54.26, approximately 29,950 shares changed hands during mid-day trading. A decline of 98% from the average daily volume of 1,302,741 shares. The stock had previously closed at $52.23.

INMD has been the subject of several research reports. Barclays upped their target price on InMode from $27.00 to $45.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 6th. Zacks Investment Research raised InMode from a “hold” rating to a “strong-buy” rating and set a $45.00 target price for the company in a research note on Friday, November 8th. Canaccord Genuity initiated coverage on InMode in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $30.00 target price for the company. UBS Group initiated coverage on InMode in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $28.00 target price for the company. Finally, Robert W. Baird reaffirmed an “outperform” rating and issued a $45.00 target price (up previously from $27.00) on shares of InMode in a research note on Wednesday, November 6th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. InMode presently has a consensus rating of “Buy” and an average price target of $38.60.

The company has a quick ratio of 7.47, a current ratio of 7.83 and a debt-to-equity ratio of 0.01. The stock’s 50-day moving average is $32.28.

InMode (NASDAQ:INMD) last announced its quarterly earnings data on Tuesday, November 5th. The healthcare company reported $0.42 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.29 by $0.13. InMode had a return on equity of 50.50% and a net margin of 30.33%. The firm had revenue of $40.01 million during the quarter, compared to the consensus estimate of $35.74 million. During the same quarter in the previous year, the company posted $0.26 earnings per share. The business’s revenue was up 57.4% on a year-over-year basis. As a group, equities analysts expect that InMode Ltd. will post 1.55 earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the business. Optimum Investment Advisors bought a new stake in InMode in the third quarter valued at approximately $28,000. Patriot Financial Group Insurance Agency LLC bought a new stake in InMode in the third quarter valued at approximately $32,000. Tower Research Capital LLC TRC bought a new stake in InMode in the third quarter valued at approximately $43,000. Steward Partners Investment Advisory LLC bought a new stake in InMode in the third quarter valued at approximately $122,000. Finally, D.A. Davidson & CO. bought a new stake in InMode in the third quarter valued at approximately $273,000. Hedge funds and other institutional investors own 1.63% of the company’s stock.

InMode Company Profile (NASDAQ:INMD)

InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments.

Recommended Story: Support Level

Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.